TRIM21 and breast cancer: In addition, lower TRIM21/Ro52 expression in mutant p53 breast cancer patients is associated with a poorer clinical outcome as TRIM21/Ro52 deficiency leads to the accumulation of mutant p53 and the subsequent breast cancer progression [48].